retatrutide regulatory approval Retatrutide, a new weight loss drug not available on the market yet, is showing promising results in trials. @DrLaPook explains it's doing much more than what current medications can Demand for Unapproved Weight-Loss Drug

Ginger Vieira, author, speaker, podcast host, and type 1 diabetes advocate, has shared her personal experience with microdosing semaglutide as part of her diabetes management plan

Steroids (2014) 0, 315

Additional secondary endpoints included changes from baseline to 24 and 48 weeks in absolute body weight, BMI, and waist circumference [2]

State-level Medicaid coverage indicates whether an individual state includes obesity-indicated GLP-1s (Saxenda, Wegovy, and Zepbound) or Type 2 diabetes-indicated GLP-1s (Ozempic, Mounjaro, and Rybelsus) on its formulary or preferred drug list, including non-preferred or restricted coverage